JP2017527294A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017527294A5 JP2017527294A5 JP2017513109A JP2017513109A JP2017527294A5 JP 2017527294 A5 JP2017527294 A5 JP 2017527294A5 JP 2017513109 A JP2017513109 A JP 2017513109A JP 2017513109 A JP2017513109 A JP 2017513109A JP 2017527294 A5 JP2017527294 A5 JP 2017527294A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- strand
- sequence
- mimetic compound
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091007431 miR-29 Proteins 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 28
- 239000000203 mixture Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 8
- 210000001519 tissue Anatomy 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 230000004761 fibrosis Effects 0.000 claims 6
- 239000000556 agonist Substances 0.000 claims 5
- 239000005557 antagonist Substances 0.000 claims 5
- 125000003729 nucleotide group Chemical group 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical group C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- 230000003176 fibrotic effect Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108091028664 Ribonucleotide Proteins 0.000 claims 2
- 235000012000 cholesterol Nutrition 0.000 claims 2
- 108091088477 miR-29a stem-loop Proteins 0.000 claims 2
- 108091029716 miR-29a-1 stem-loop Proteins 0.000 claims 2
- 108091092089 miR-29a-2 stem-loop Proteins 0.000 claims 2
- 108091066559 miR-29a-3 stem-loop Proteins 0.000 claims 2
- 108091007432 miR-29b Proteins 0.000 claims 2
- 108091047189 miR-29c stem-loop Proteins 0.000 claims 2
- 108091054490 miR-29c-2 stem-loop Proteins 0.000 claims 2
- 239000003595 mist Substances 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- 239000002336 ribonucleotide Substances 0.000 claims 2
- 125000002652 ribonucleotide group Chemical group 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000004362 Penile Induration Diseases 0.000 claims 1
- 208000020758 Peyronie disease Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 230000001276 controlling effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
- 210000002435 tendon Anatomy 0.000 claims 1
- 239000006200 vaporizer Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462047562P | 2014-09-08 | 2014-09-08 | |
| US62/047,562 | 2014-09-08 | ||
| PCT/US2015/049018 WO2016040373A1 (en) | 2014-09-08 | 2015-09-08 | Mir-29 mimics and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017527294A JP2017527294A (ja) | 2017-09-21 |
| JP2017527294A5 true JP2017527294A5 (enExample) | 2018-10-18 |
| JP6837963B2 JP6837963B2 (ja) | 2021-03-03 |
Family
ID=55436959
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017513109A Expired - Fee Related JP6837963B2 (ja) | 2014-09-08 | 2015-09-08 | Ｍｉｒ−２９模倣物およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US9376681B2 (enExample) |
| EP (1) | EP3201213B1 (enExample) |
| JP (1) | JP6837963B2 (enExample) |
| KR (1) | KR20170068452A (enExample) |
| CN (1) | CN107108685B (enExample) |
| AU (1) | AU2015315298B2 (enExample) |
| BR (1) | BR112017004648A2 (enExample) |
| CA (1) | CA2960387A1 (enExample) |
| CL (1) | CL2017000564A1 (enExample) |
| IL (1) | IL250952A0 (enExample) |
| MX (1) | MX382425B (enExample) |
| PH (1) | PH12017500424A1 (enExample) |
| RU (1) | RU2712511C2 (enExample) |
| WO (1) | WO2016040373A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2621161T3 (es) | 2007-07-31 | 2017-07-03 | The Board Of Regents Of The University Of Texas System | Familia de micro-ARN que modula la fibrosis y usos de la misma |
| GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
| RU2712511C2 (ru) | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
| US10801025B2 (en) | 2016-07-26 | 2020-10-13 | Indiana University Research And Technology Corporation | MicroRNA therapy for pancreatic cancer |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| CN107982536B (zh) * | 2017-10-27 | 2021-04-09 | 上海交通大学医学院附属第九人民医院 | 一种药物作用靶点的组合物和应用 |
| CA3083279A1 (en) * | 2017-11-30 | 2019-06-06 | MiRagen Therapeutics, Inc. | Mir29 mimics for the treatment of ocular fibrosis |
| US11021712B1 (en) | 2018-09-07 | 2021-06-01 | Washington University | MiRNA mimics and uses thereof |
| CN109234381B (zh) * | 2018-10-22 | 2021-06-18 | 云南省玉溪市人民医院 | miR-2682-5p作为肾纤维化标志物的应用 |
| WO2020181107A1 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Microrna mimics and uses thereof |
| WO2020181130A2 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| US12097222B2 (en) | 2019-06-06 | 2024-09-24 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
| US11607428B2 (en) | 2019-06-06 | 2023-03-21 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
| EP4114938A4 (en) * | 2020-03-04 | 2025-02-19 | The Trustees of Indiana University | Methods to re-engage a fetal wound healing pathway for adult skin repair |
| CN111249466B (zh) * | 2020-03-14 | 2022-04-15 | 浙江大学医学院附属第一医院 | 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用 |
| CN111449025A (zh) * | 2020-04-02 | 2020-07-28 | 华北理工大学 | miRNAs在抑制大鼠肝纤维化中的应用 |
| US11987793B2 (en) | 2020-05-03 | 2024-05-21 | Washington University | Compositions and methods for prevention of bladder fibrosis |
| CN111647656A (zh) * | 2020-05-15 | 2020-09-11 | 华中科技大学同济医学院附属同济医院 | mir-29a基因在检测肝癌及肝纤维化中的应用及所述基因条件敲入小鼠的构建方法 |
| CN112226436B (zh) * | 2020-10-20 | 2021-05-18 | 南京医科大学 | MiR-29海绵、包含miR-29海绵的核酸构建体及其应用 |
| GB202016863D0 (en) * | 2020-10-23 | 2020-12-09 | Causeway Therapeutics Ltd | Microrna-29 compounds, compositions and uses in therapy |
| US20250304956A1 (en) * | 2021-08-06 | 2025-10-02 | Leadermed Champion Limited | miRNA-BASED COMPOSITIONS AND METHODS OF USE THEREOF |
| AU2023445724A1 (en) * | 2023-04-28 | 2025-11-06 | Causeway Therapeutics Limited | Microrna-29 compounds, compositions and uses in therapy, and methods for evaluating tendinopathic lesions |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
| WO1995003843A1 (en) | 1993-07-30 | 1995-02-09 | The Regents Of The University Of California | Endocardial infusion catheter |
| US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
| US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
| ATE321882T1 (de) | 1997-07-01 | 2006-04-15 | Isis Pharmaceuticals Inc | Zusammensetzungen und verfahren zur verabreichung von oligonukleotiden über die speiseröhre |
| US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
| US6716242B1 (en) | 1999-10-13 | 2004-04-06 | Peter A. Altman | Pulmonary vein stent and method for use |
| US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
| US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
| US7247313B2 (en) | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
| US6589286B1 (en) | 2001-09-12 | 2003-07-08 | Jason Litner | Eustachian tube stent |
| EP2390328A1 (en) * | 2001-09-28 | 2011-11-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7236821B2 (en) | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
| AU2003266014B2 (en) | 2002-05-06 | 2009-05-14 | Alnylam Pharmaceuticals, Inc. | Methods for delivery of nucleic acids |
| WO2004004602A1 (en) | 2002-07-08 | 2004-01-15 | Abbott Laboratories Vascular Enterprises Limited | Drug eluting stent and methods of manufacture |
| US7294329B1 (en) | 2002-07-18 | 2007-11-13 | Advanced Cardiovascular Systems, Inc. | Poly(vinyl acetal) coatings for implantable medical devices |
| US7232573B1 (en) | 2002-09-26 | 2007-06-19 | Advanced Cardiovascular Systems, Inc. | Stent coatings containing self-assembled monolayers |
| US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
| US7144422B1 (en) | 2002-11-13 | 2006-12-05 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making the same |
| US7105018B1 (en) | 2002-12-30 | 2006-09-12 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent cover and method of use |
| US7156869B1 (en) | 2003-01-27 | 2007-01-02 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and delivery system with tapered stent in shoulder region |
| US7041127B2 (en) | 2003-05-28 | 2006-05-09 | Ledergerber Walter J | Textured and drug eluting coronary artery stent |
| EP1648914A4 (en) * | 2003-07-31 | 2009-12-16 | Regulus Therapeutics Inc | OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA |
| US7055237B2 (en) | 2003-09-29 | 2006-06-06 | Medtronic Vascular, Inc. | Method of forming a drug eluting stent |
| US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
| BRPI0508073A (pt) | 2004-02-26 | 2007-07-17 | Kardia Pty Ltd V | método e aparelho para isolar substancialmente circulação cardìaca da circulação sistêmica aparelho para perfundir o coração com um agente terapêutico, cateter de obstrução para obstruir fluxo entre um vaso principal e um ou mais vasos ramificados, método para administrar um agente terapêutico ao coração e estrutura de suporte percutaneamente administrável para manter patência do sinus coronário |
| US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
| WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007031333A2 (en) | 2005-09-15 | 2007-03-22 | Novosom Ag | Improvements in or relating to amphoteric liposomes |
| EP2388327A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
| WO2007095387A2 (en) | 2006-02-17 | 2007-08-23 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
| EP2064223B1 (en) * | 2006-09-22 | 2013-04-24 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| ES2621161T3 (es) | 2007-07-31 | 2017-07-03 | The Board Of Regents Of The University Of Texas System | Familia de micro-ARN que modula la fibrosis y usos de la misma |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| EP2096171A1 (en) * | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
| KR20110082515A (ko) | 2008-09-04 | 2011-07-19 | 유니베르시태트 취리히 | 피부 경화증의 치료 |
| WO2010039502A2 (en) | 2008-09-23 | 2010-04-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Micrornas in idiopathic pulmonary fibrosis |
| US20120022143A1 (en) * | 2009-03-27 | 2012-01-26 | Merck Sharp & Dohme Corp | RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA) |
| DK2427472T3 (en) | 2009-05-05 | 2016-09-12 | Miragen Therapeutics | Lipophilic polynukleotidkonjugater |
| JP2011004708A (ja) * | 2009-06-29 | 2011-01-13 | Univ Of Tokyo | ｓｍａｌｌＲＮＡ二本鎖およびヘアピン型ＲＮＡの設計方法 |
| US9096850B2 (en) | 2009-08-24 | 2015-08-04 | Sirna Therapeutics, Inc. | Segmented micro RNA mimetics |
| EP2371370A1 (en) * | 2010-04-01 | 2011-10-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
| WO2012131670A2 (en) * | 2011-03-28 | 2012-10-04 | Rosetta Genomics Ltd | Methods for lung cancer clasification |
| AU2012242761A1 (en) * | 2011-04-12 | 2013-10-31 | Beth Israel Deaconess Medical Center, Inc. | Micro-RNA inhibitors and their uses in disease |
| WO2013032962A2 (en) * | 2011-08-28 | 2013-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease |
| BR112014012288A2 (pt) | 2011-11-22 | 2017-05-23 | Intermune Inc | métodos para diagnosticar e tratar fibrose pulmonar idiopática |
| GB201400598D0 (en) * | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
| US10150966B2 (en) | 2014-03-04 | 2018-12-11 | Hirofumi Yamamoto | RNA sequence having anti-tumour activity |
| RU2712511C2 (ru) | 2014-09-08 | 2020-01-29 | Мираген Терапеутикс, Инк. | Миметики mir-29 и пути их применения |
-
2015
- 2015-09-08 RU RU2017111775A patent/RU2712511C2/ru active
- 2015-09-08 CA CA2960387A patent/CA2960387A1/en not_active Abandoned
- 2015-09-08 AU AU2015315298A patent/AU2015315298B2/en not_active Ceased
- 2015-09-08 WO PCT/US2015/049018 patent/WO2016040373A1/en not_active Ceased
- 2015-09-08 US US14/848,085 patent/US9376681B2/en not_active Expired - Fee Related
- 2015-09-08 CN CN201580057333.0A patent/CN107108685B/zh not_active Expired - Fee Related
- 2015-09-08 BR BR112017004648A patent/BR112017004648A2/pt not_active Application Discontinuation
- 2015-09-08 EP EP15840320.4A patent/EP3201213B1/en active Active
- 2015-09-08 MX MX2017003018A patent/MX382425B/es unknown
- 2015-09-08 JP JP2017513109A patent/JP6837963B2/ja not_active Expired - Fee Related
- 2015-09-08 KR KR1020177008019A patent/KR20170068452A/ko not_active Withdrawn
-
2016
- 2016-06-07 US US15/175,636 patent/US9994847B2/en not_active Expired - Fee Related
-
2017
- 2017-03-06 IL IL250952A patent/IL250952A0/en unknown
- 2017-03-07 PH PH12017500424A patent/PH12017500424A1/en unknown
- 2017-03-08 CL CL2017000564A patent/CL2017000564A1/es unknown
-
2018
- 2018-06-07 US US16/002,845 patent/US20190127734A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017527294A5 (enExample) | ||
| RU2017111775A (ru) | Имитаторы mir-29 и пути их применения | |
| Shirbhate et al. | Understanding the role of ACE-2 receptor in pathogenesis of COVID-19 disease: a potential approach for therapeutic intervention | |
| US11421232B2 (en) | Compositions and methods for treatment of cardiac diseases | |
| EP2499248B1 (en) | Antisense antiviral compound and method for treating influenza viral infection | |
| JP2018520685A (ja) | Ｂ型肝炎ウイルスに対する組成物および薬剤ならびにその使用 | |
| JP2011507857A5 (enExample) | ||
| JP2011256204A5 (enExample) | ||
| JP2015523855A (ja) | Ａｐｏａ１及びａｂｃａ１発現を調節するための組成物及び方法 | |
| JP2014519333A5 (enExample) | ||
| JP7318166B2 (ja) | マイクロｒｎａ２２の阻害剤 | |
| TW201406774A (zh) | 微ｒｎａ之ｍｉｒ－１５家族之抑制劑 | |
| JP2014516027A5 (enExample) | ||
| US20220307028A1 (en) | Compositions and methods for mitigation of ischemic reperfusion injury | |
| JP2011507859A5 (enExample) | ||
| US20180055869A1 (en) | Compositions and methods for modulating rna | |
| ATE491715T1 (de) | Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten | |
| US20160145615A1 (en) | Agonists of ddah1 for treating endothelial dysfunction | |
| JP2016518820A5 (enExample) | ||
| CA2887069A1 (en) | Amphiregulin-specific double-helical oligo-rna, double-helical oligo-rna structure comprising double-helical oligo-rna, and composition for preventing or treating respiratory diseases containing same | |
| WO2018070510A1 (ja) | 筋分化誘導剤 | |
| JP7692829B2 (ja) | Ｍｕｒｆ１を標的とする核酸医薬 | |
| JP7639035B2 (ja) | 骨量減少または筋機能低下に関連する病的状態を治療する際に使用するためのマイクロｒｎａ１９ａ／１９ｂ | |
| WO2024239039A1 (en) | Methods of treating pulmonary fibrosis | |
| JP7498448B2 (ja) | ＳＮＨＧ１２遺伝子に由来するｎｃＲＮＡの発現抑制剤を有効成分とするがん増殖抑制剤 |